About: Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study
Creator	De Luca, Daniele Capoluongo, Ettore Luca, De Rigo, Vincent
Source	PMC
abstract	BACKGROUND: Secretory phospholipase A2 (sPLA2) is a group of enzymes involved in lung tissue inflammation and surfactant catabolism. sPLA2 plays a role in adults affected by acute lung injury and seems a promising therapeutic target. Preliminary data allow foreseeing the importance of such enzyme in some critical respiratory diseases in neonates and infants, as well. Our study aim is to clarify the role of sPLA2 and its modulators in the pathogenesis and clinical severity of hyaline membrane disease, infection related respiratory failure, meconium aspiration syndrome and acute respiratory distress syndrome. sPLA2 genes will also be sequenced and possible genetic involvement will be analysed. METHODS/DESIGN: Multicentre, international, translational study, including several paediatric and neonatal intensive care units and one coordinating laboratory. Babies affected by the above mentioned conditions will be enrolled: broncho-alveolar lavage fluid, serum and whole blood will be obtained at definite time-points during the disease course. Several clinical, respiratory and outcome data will be recorded. Laboratory researchers who perform the bench part of the study will be blinded to the clinical data. DISCUSSION: This study, thanks to its multicenter design, will clarify the role(s) of sPLA2 and its pathway in these diseases: sPLA2 might be the crossroad between inflammation and surfactant dysfunction. This may represent a crucial target for new anti-inflammatory therapies but also a novel approach to protect surfactant or spare it, improving alveolar stability, lung mechanics and gas exchange.
has issue date	2011-11-08(xsd:dateTime)
bibo:doi	10.1186/1471-2431-11-101
bibo:pmid	22067747
has license	cc-by
sha1sum (hex)	33368b3bf3f05e99890999c844200b1bc8a949c1
schema:url	https://doi.org/10.1186/1471-2431-11-101
resource representing a document's title	Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study
has PubMed Central identifier	PMC3247178
has PubMed identifier	22067747
schema:publication	BMC Pediatr
resource representing a document's body	covid:33368b3bf3f05e99890999c844200b1bc8a949c1#body_text
is schema:about of	named entity 'alveolar' named entity 'Preliminary' named entity 'therapeutic' named entity 'neonates' named entity 'phospholipase' named entity 'GAS EXCHANGE' named entity 'REPRESENT' named entity 'CATABOLISM' named entity 'study' named entity 'adults' named entity 'respiratory failure' named entity 'perform' named entity 'sPLA2' named entity 'blinded' named entity 'represent' named entity 'laboratory' named entity 'multicenter' named entity 'Methods' named entity 'Background' named entity 'Laboratory' named entity 'anti-inflammatory' named entity 'genes' named entity 'researchers' named entity 'coordinating' named entity 'infants' named entity 'sPLA2' named entity 'neonates' named entity 'lung' named entity 'pathogenesis' named entity 'group of enzymes' named entity 'catabolism' named entity 'gas exchange' named entity 'surfactant' named entity 'inflammation' named entity 'phospholipase A2' named entity 'Secretory' named entity 'Secretory' named entity 'lung injury' named entity 'pro-inflammatory' named entity 'sPLA2' named entity 'sPLA2' named entity 'respiratory rate' named entity 'ARDS' named entity 'catabolism' named entity 'BALF' named entity 'neonatal' named entity 'surfactant' named entity 'Congenital' named entity 'Budesonide' named entity 'supernatant' named entity 'clinical signs' named entity 'respiratory conditions' named entity 'control group' named entity 'surfactant' named entity 'internal validity' named entity 'surfactant' named entity 'urea' named entity 'surfactant' named entity 'bronchoscopic' named entity 'intensive care unit' named entity 'catabolism' named entity 'conventional ventilation' named entity 'standard curve' named entity 'oxygen therapy' named entity 'budesonide' named entity 'Paediatrics' named entity 'sPLA2' named entity 'surfactant' named entity 'consent form' named entity 'polymorphisms' named entity 'neonatologists' named entity 'polymorphisms' named entity 'enzyme activity' named entity 'sPLA2' named entity 'polymorphisms' named entity 'vicious cycle' named entity 'IL1' named entity 'sPLA2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software